Assyro AI

Orange Book product · Brand (NDA)

AIRDUO DIGIHALER

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Brand (NDA)NDA 208799DISCN TEVA PHARM

At a glance

Jul 12, 2019

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 12, 2019

    7 yr ago

  2. Today

  3. Patent 10195375 expires

    Listed drug product patent expiration.

    Feb 14, 2031

    in 4 yr 9 mo

  4. Patent 10195375*PED expires

    Listed listed patent expiration.

    Aug 14, 2031

    in 5 yr 3 mo

  5. Patent 9066957 expires

    Listed drug product patent expiration.

    Oct 06, 2034

    in 8 yr 5 mo

  6. Patent 9066957*PED expires

    Listed listed patent expiration.

    Apr 06, 2035

    in 8 yr 11 mo

  7. Patent 10918816 expires

    Listed drug product patent expiration.

    Dec 14, 2035

    in 9 yr 8 mo

  8. Patent 10918816*PED expires

    Listed listed patent expiration.

    Jun 14, 2036

    in 10 yr 2 mo

  9. Patent 11969544 expires

    Listed drug product patent expiration.

    Aug 20, 2039

    in 13 yr 4 mo

  10. Patent 11344685 expires

    Listed drug product patent expiration.

    Sep 26, 2039

    in 13 yr 6 mo

  11. Patent 11969544*PED expires

    Listed listed patent expiration.

    Feb 20, 2040

    in 13 yr 10 mo

  12. Patent 11344685*PED expires

    Listed listed patent expiration.

    Mar 26, 2040

    in 14 yr

  13. Patent 11173259 expires

    Listed drug product patent expiration.

    Jul 06, 2040

    in 14 yr 3 mo

  14. Patent 11173259*PED expires

    Listed listed patent expiration.

    Jan 06, 2041

    in 14 yr 9 mo

Pharmaceutical detail

Active ingredient

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Strength

0.113MG/INH;EQ 0.014MG BASE/INH

Dosage form

POWDER

Route

INHALATION

TE code

Not listed

Application

NDA 208799

Product number

005

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10195375Feb 14, 2031in 4 yr 9 mo
Product
10195375*PEDAug 14, 2031in 5 yr 3 mo
9066957Oct 06, 2034in 8 yr 5 mo
ProductU-645
9066957*PEDApr 06, 2035in 8 yr 11 mo
10918816Dec 14, 2035in 9 yr 8 mo
Product
10918816*PEDJun 14, 2036in 10 yr 2 mo
11969544Aug 20, 2039in 13 yr 4 mo
Product
11344685Sep 26, 2039in 13 yr 6 mo
Product
11969544*PEDFeb 20, 2040in 13 yr 10 mo
11344685*PEDMar 26, 2040in 14 yr
11173259Jul 06, 2040in 14 yr 3 mo
Product
11173259*PEDJan 06, 2041in 14 yr 9 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.